NARLAL2试验:局部晚期非小细胞肺癌氟脱氧葡萄糖引导的异质性放疗剂量递增后6个月内的毒性
斯堪的纳维亚多中心III期随机试验NARLAL2纳入350例局部晚期非小细胞肺癌患者,随机接受标准66 Gy或氟脱氧葡萄糖引导的异质性剂量递增放疗(平均肿瘤剂量88 Gy)。两组早期毒性无差异,异质性剂量递增未增加6个月内毒性。
要点
- 两组早期毒性无差异,标准组与递增组≥3级毒性最大聚合等级分别为35%和1%
- 放疗期间≥2级食管炎标准组28.1% vs 递增组25.6%,≥3级7.3% vs 4.1%
- ≥2级肺炎标准组15.7% vs 递增组20.3%,≥3级3.9% vs 5.8%
核心结论
- 异质性剂量递增未增加早期毒性,尽管原发肿瘤平均剂量达88 Gy,作者认为这是局部晚期非小细胞肺癌放疗剂量递增的有吸引力的策略。
研究设计与样本
- 斯堪的纳维亚7家机构的多中心III期随机试验NARLAL2(NCT02354274),2015年1月至2023年3月随机分配350例局部晚期非小细胞肺癌患者。
- 纳入标准包括体能状态0-1、NSCLC分期IIB-IIIB、可实施66 Gy/33次治疗计划,随机前为每例患者制定两个平均肺剂量和V20Gy匹配且严格正常组织剂量约束的治疗计划。
- 按治疗分析包括标准组178例和剂量递增组172例(平均肿瘤剂量88 Gy)。
- 同步化疗为顺铂/卡铂联合长春瑞滨。
主要发现
- 标准组和递增组的中位大体肿瘤体积分别为54 cm3和61 cm3,计划靶体积分别为321 cm3和339 cm3。
- 放疗期间≥2级食管炎标准组28.1% vs 递增组25.6%,≥3级食管炎标准组7.3% vs 递增组4.1%。
- ≥2级肺炎标准组15.7% vs 递增组20.3%,≥3级肺炎标准组3.9% vs 递增组5.8%。
- 两组所有毒性聚合的早期毒性最大等级≥3级为35%,5级为1%。
- 4例患者死于可能的治疗相关毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation dose escalation for locally advanced non-small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLAL2 (ClinicalTrials.gov identifier: NCT02354274) used a novel approach to dose escalation: heterogeneous escalation driven by the fluorodeoxyglucose positron emission tomography-avid region, with strict normal tissue dose constraints. We report early toxicity within 6 months of random assignment. MATERIALS AND METHODS: Patients were recruited from seven institutions in Scandinavia. Eligibility criteria included performance status 0-1, NSCLC stage IIB-IIIB, and feasibility of delivering 66 Gy/33 fraction treatment plan. Patients were randomly assigned between standard (66 Gy) and heterogeneously dose-escalated radiotherapy. Two treatment plans were made for each patient before random assignment with matched mean lung dose and V20Gy, and strict dose constraints for all normal tissues. Toxicity was evaluated weekly during radiotherapy, and every 3 months after random assignment. Concurrent chemotherapy was cisplatin/carboplatin and vinorelbine. RESULTS: Between January 2015 and March 2023, 350 patients were randomly assigned. The as-treated analysis included 178 patients in the standard and 172 in dose-escalated (mean tumor dose 88 Gy) arms. Median gross tumor and planning target volumes were, respectively, 54 cm3 and 321 cm3 (standard arm) and 61 cm3 and 339 cm3 (escalated arm). No difference in early toxicity between the two arms was observed. Grade 2 esophagitis during radiotherapy was 28.1% and 25.6%, grade 3 esophagitis 7.3% and 4.1%, grade 2 pneumonitis 15.7% and 20.3%, and grade 3 pneumonitis 3.9% and 5.8% in standard and escalated arms, respectively. For both arms, the maximum grade of early toxicity aggregated over all toxicities was 35% and 1% for grades ≥3 and 5, respectively. Four patients died from potential treatment-related toxicity. CONCLUSION: Heterogeneous dose escalation did not increase early toxicity despite delivery of 88 Gy mean dose to the primary tumor, demonstrating this as an attractive strategy for LA-NSCLC radiotherapy dose escalation.
引用
- Schytte T, Knap MM, Kristiansen C, et al. Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. J Clin Oncol. 2025. PMID: 40249893. doi:10.1200/JCO-24-01386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。